ERBB2 and melanoma: In non-small cell lung cancer, 46.5% of level 1/2 actional alterations were EGFR mutations, followed by ALK fusions (31.5%) and ROS1 fusions (8.7%); in melanoma were BRAF V600 mutation (98.8%%); in gastrointestinal stromal were KIT mutations (88.9%) and PDGFRA mutations (11.1%); in BRCA were ERBB2 amplification (44.4%) and PIK3CA mutations (43.7%); in THCA were RET mutations or fusions (83.9%) and NTRK fusions (16.1%).